ABBOTT ROLLING OUT LCx CHLAMYDIA TEST IN U.S. FOLLOWING 510(K) CLEARANCE; CORPORATE SALES HIT $10 BIL. IN 1995, UP 9.6%; HOSPITAL/LAB SALES GAIN 4.6%
This article was originally published in The Gray Sheet
Executive Summary
Abbott Laboratories is launching its LCx gene amplification test for chlamydia following receipt of 510(k) clearance from FDA on Dec. 8. The urine-based test is the first semi-automated gene amplification test to reach the U.S. market.